DNA vaccine expressing herpes simplex virus 1 glycoprotein C and D protects mice against herpes simplex keratitis (scientific article published on 18 November 2017)

Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compa

Q35275146

A Herpes Simplex Virus Type 1 Human Asymptomatic CD8+ T-Cell Epitopes-Based Vaccine Protects Against Ocular Herpes in a "Humanized" HLA Transgenic Rabbit Model

Q35769258

Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.

Q35863299

Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.

Q36080869

HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects

Q36097352

Immune evasion by herpes simplex virus type 1, strategies for virus survival

Q36372405

Mammaglobin-A is a target for breast cancer vaccination

Q36710956

Blocking Immune Evasion as a Novel Approach for Prevention and Treatment of Herpes Simplex Virus Infection

Q37060288

Potential of nanocarriers in genetic immunization

Q37347841

Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials

Q37392189

Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine

Q37439603

Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2.

Q38348319

Prophylactic and therapeutic DNA vaccines against Chagas disease

Q38426148

Using Plasmids as DNA Vaccines for Infectious Diseases

Q38535937

Mucin-like Region of Herpes Simplex Virus Type 1 Attachment Protein Glycoprotein C (gC) Modulates the Virus-Glycosaminoglycan Interaction

Q38854789

A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation

Q40665953

Topical Administration Is a Promising Inoculating Route versus Intramuscular Inoculation for the Nanoparticle-Carried DNA Vaccine to Prevent Corneal Infections

Q40877824

Nasal delivery of vaccines

Q41156926

Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis

Q43454630

Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis

Q45370073

Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains

Q45453302

Mechanism of complement inactivation by glycoprotein C of herpes simplex virus

Q45764786

Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins

Q45785300

Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.

Q50995133

[A kinetic study of gamma interferon production in herpes simplex virus-1 DNA prime-protein boost regimen comparing to DNA or subunit vaccination].

Q52697937

Use of nanocarriers for transdermal vaccine delivery

Q81591155

Characterization of pDNA-TMC Nanoparticle Interaction and Stability